SK284572B6 - Vakcíny obsahujúce adjuvans LTB a použitie podjednotky B tepelne-labilného enterotoxínu - Google Patents

Vakcíny obsahujúce adjuvans LTB a použitie podjednotky B tepelne-labilného enterotoxínu Download PDF

Info

Publication number
SK284572B6
SK284572B6 SK776-2000A SK7762000A SK284572B6 SK 284572 B6 SK284572 B6 SK 284572B6 SK 7762000 A SK7762000 A SK 7762000A SK 284572 B6 SK284572 B6 SK 284572B6
Authority
SK
Slovakia
Prior art keywords
subunit
ltb
vaccine
immunogen
mucosal
Prior art date
Application number
SK776-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK7762000A3 (en
Inventor
Etienne Agsteribbe
Rudi Brands
Haan Lolke De
Scharrenburg Gustaaf Johan Marie Van
Willem Ronald Verweij
Jan Christiaan Wilschut
Original Assignee
Duphar International Research B. V.
Universiteit Van Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research B. V., Universiteit Van Groningen filed Critical Duphar International Research B. V.
Publication of SK7762000A3 publication Critical patent/SK7762000A3/sk
Publication of SK284572B6 publication Critical patent/SK284572B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SK776-2000A 1997-11-25 1998-11-24 Vakcíny obsahujúce adjuvans LTB a použitie podjednotky B tepelne-labilného enterotoxínu SK284572B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203671A EP0919243A1 (fr) 1997-11-25 1997-11-25 Vaccin dont l'adjuvant est constitué de sous-unités B de l'entérotoxine thermolabile (LTB) d'Escherichia coli
PCT/EP1998/007553 WO1999026654A1 (fr) 1997-11-25 1998-11-24 Vaccins a adjuvant de ltb

Publications (2)

Publication Number Publication Date
SK7762000A3 SK7762000A3 (en) 2000-11-07
SK284572B6 true SK284572B6 (sk) 2005-06-02

Family

ID=8228966

Family Applications (1)

Application Number Title Priority Date Filing Date
SK776-2000A SK284572B6 (sk) 1997-11-25 1998-11-24 Vakcíny obsahujúce adjuvans LTB a použitie podjednotky B tepelne-labilného enterotoxínu

Country Status (25)

Country Link
US (1) US6793928B1 (fr)
EP (2) EP0919243A1 (fr)
JP (1) JP4235359B2 (fr)
KR (1) KR100575019B1 (fr)
CN (1) CN1227032C (fr)
AT (1) ATE238809T1 (fr)
AU (1) AU747061C (fr)
BR (1) BR9815413A (fr)
CA (1) CA2311492C (fr)
CZ (1) CZ299770B6 (fr)
DE (1) DE69814177T2 (fr)
DK (1) DK1071456T3 (fr)
ES (1) ES2198089T3 (fr)
HK (1) HK1031102A1 (fr)
HU (1) HU226214B1 (fr)
IL (2) IL135905A0 (fr)
NO (1) NO324690B1 (fr)
NZ (1) NZ504396A (fr)
PL (1) PL190925B1 (fr)
PT (1) PT1071456E (fr)
RU (1) RU2211050C2 (fr)
SK (1) SK284572B6 (fr)
TR (1) TR200001485T2 (fr)
UA (1) UA72199C2 (fr)
WO (1) WO1999026654A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB2353472A (en) * 1998-05-08 2001-02-28 Univ Bristol Vaccine
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
KR20010043441A (ko) 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 백신용 면역조절제
EP1221970B1 (fr) * 1999-10-18 2014-02-19 Novartis Vaccines and Diagnostics, Inc. Compositions et methodes destines a stimuler une reponse immune contre des agents infectieux
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
US20060002960A1 (en) * 2003-12-09 2006-01-05 Paul Zoeteweij GM1 binding deficient exotoxins for use as immunoadjuvants
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2664168A1 (fr) 2006-10-12 2008-04-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Proteine de fusion de transcriptase inverse de la telomerase, nucleotides qui codent pour elle et ses utilisations
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US8821885B2 (en) 2007-08-27 2014-09-02 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2009085355A2 (fr) 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics Llc Système de prélèvement et de transport d'échantillons biologiques et procédés d'utilisation
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
US10208093B2 (en) 2013-12-16 2019-02-19 Agricultural Technology Research Institute Plasmid, method and kit thereof for producing heat labile enterotoxin B-subunit
WO2016183292A1 (fr) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Procédés rapides pour l'extraction d'acides nucléiques provenant d'échantillons biologiques
MX2020004434A (es) * 2017-11-01 2020-08-06 Merck Sharp & Dohme Formulaciones estables de citomegalovirus.
CA3087569A1 (fr) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Agents de phosphatase alcaline pour le traitement de troubles neurodeveloppementaux
EP3773686B1 (fr) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Agents au phosphatase alcaline pour le traitement de troubles dus à une exposition à des radiations
CA3094173A1 (fr) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Formulations de phosphatase alcaline intestinale
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (fr) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IL92578A0 (en) * 1988-12-07 1990-08-31 Univ Leicester Heat-labile toxin b subunit fusion proteins and their preparation
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB

Also Published As

Publication number Publication date
DK1071456T3 (da) 2003-06-02
KR100575019B1 (ko) 2006-05-02
NZ504396A (en) 2002-09-27
AU1875099A (en) 1999-06-15
DE69814177T2 (de) 2004-04-08
CA2311492C (fr) 2011-10-18
CN1227032C (zh) 2005-11-16
HU226214B1 (en) 2008-06-30
EP0919243A1 (fr) 1999-06-02
NO324690B1 (no) 2007-12-03
PT1071456E (pt) 2003-09-30
HUP0100058A3 (en) 2003-03-28
PL340635A1 (en) 2001-02-12
BR9815413A (pt) 2000-10-17
CA2311492A1 (fr) 1999-06-03
NO20002613D0 (no) 2000-05-22
AU747061B2 (en) 2002-05-09
SK7762000A3 (en) 2000-11-07
UA72199C2 (en) 2005-02-15
EP1071456B1 (fr) 2003-05-02
RU2211050C2 (ru) 2003-08-27
JP4235359B2 (ja) 2009-03-11
KR20010032425A (ko) 2001-04-16
AU747061C (en) 2005-02-24
HK1031102A1 (en) 2001-06-01
IL135905A (en) 2006-08-01
CZ299770B6 (cs) 2008-11-19
EP1071456A1 (fr) 2001-01-31
ATE238809T1 (de) 2003-05-15
DE69814177D1 (de) 2003-06-05
HUP0100058A1 (hu) 2001-05-28
PL190925B1 (pl) 2006-02-28
NO20002613L (no) 2000-05-22
WO1999026654A1 (fr) 1999-06-03
CZ20001895A3 (cs) 2000-10-11
TR200001485T2 (tr) 2001-12-21
IL135905A0 (en) 2001-05-20
US6793928B1 (en) 2004-09-21
JP2001523729A (ja) 2001-11-27
CN1280504A (zh) 2001-01-17
ES2198089T3 (es) 2004-01-16

Similar Documents

Publication Publication Date Title
EP1071456B1 (fr) Vaccins avec un adjuvant constitue de ltb
US8182821B2 (en) Flu vaccine admixture of mannan and flu antigen
Tamura et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine
EP1117435A1 (fr) Holotoxine mutante du cholera utilisee comme adjuvant
NO323555B1 (no) Influensavaksine, farmasoytisk utstyr og anvendelse av kitosan.
de Haan et al. Mutational analysis of the role of ADP‐ribosylation activity and GM1‐binding activity in the adjuvant properties of the Escherichia coli heat‐labile enterotoxin towards intranasally administered keyhole limpet hemocyanin
Larsen et al. Effects of DNA dose, route of vaccination, and coadministration of porcine interleukin-6 DNA on results of DNA vaccination against influenza virus infection in pigs
WO1995009649A1 (fr) Compositions de vaccins
Glück Intranasal immunization against influenza
JP5913406B2 (ja) 変異型大腸菌易熱性エンテロトキシン
WO2008037033A1 (fr) Vaccin contre la grippe constitué d'un mélange de mannane et d'antigène de la grippe
Morein et al. New ISCOMs meet unsettled vaccine demands
MXPA00005127A (en) Vaccines with an ltb adjuvant
PT721782E (pt) Vacina contra a gripe contendo toxina da tosse convulsa

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: ABBOTT BIOLOGICALS B.V., CP WEESP, NL

Effective date: 20120830

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20131124